Dr. Keith Stockerl-Goldstein
Claim this profileWashington University School of Medicine
Expert in Multiple Myeloma
Expert in Plasma Cell Neoplasm
28 reported clinical trials
46 drugs studied
About Keith Stockerl-Goldstein
Education:
- Obtained a BA in Biology from Washington University, Saint Louis, Missouri, 1986.
- Earned an MD from the University of California Los Angeles (UCLA) School of Medicine, 1991.
- Completed Residency in Internal Medicine at Stanford University Hospital, 1993.
- Undertook Fellowships in Bone Marrow Transplantation (1995) and Medical Oncology (1996) at Stanford University School of Medicine.
Experience:
- Former Clinical Director of Adult Bone Marrow Transplantation Unit at Stanford University School of Medicine.
- Currently serves as Program Director for Hematology-Medical Oncology & Hematology Focused Fellowship Training Program at Washington University School of Medicine.
- Holds the position of Associate Program Director for Bone Marrow Transplantation at the same institution.
Area of expertise
1Multiple Myeloma
Global LeaderStage IV
Stage III
Stage I
2Plasma Cell Neoplasm
Global LeaderStage III
Stage IV
Affiliated Hospitals
Clinical Trials Keith Stockerl-Goldstein is currently running
Motixafortide + G-CSF
for Multiple Myeloma
This study includes extended CD34+ profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad-induction followed by motixafortide + G-CSF mobilization, and in addition, assesses the pharmacodynamics (PD) of motixafortide following "standard" (\~12 hours) vs "early" (\~16 hours) dosing. The investigators hypothesize that quad-induction may alter the stem cell subsets within the mobilized graft. The investigators further hypothesize that standard and early dosing strategies will result in comparable mobilization and stem cell collection rates.
Recruiting1 award Phase 16 criteria
CIML NK Cell Therapy
for Acute Myeloid Leukemia
This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (\>60% any grades or \>30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).
Recruiting1 award Phase 2
More about Keith Stockerl-Goldstein
Clinical Trial Related1 year of experience running clinical trials · Led 28 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Keith Stockerl-Goldstein has experience with
- Lenalidomide
- Dexamethasone
- Daratumumab
- Bortezomib
- Melphalan
- Isatuximab
Breakdown of trials Keith Stockerl-Goldstein has run
Multiple Myeloma
Plasma Cell Neoplasm
Acute Myeloid Leukemia
Graft-versus-Host Disease
- Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
- ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
- Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Keith Stockerl-Goldstein specialize in?
Keith Stockerl-Goldstein focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved Stage IV patients, or patients who are Stage III.
Is Keith Stockerl-Goldstein currently recruiting for clinical trials?
Yes, Keith Stockerl-Goldstein is currently recruiting for 8 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Keith Stockerl-Goldstein has studied deeply?
Yes, Keith Stockerl-Goldstein has studied treatments such as Lenalidomide, Dexamethasone, Daratumumab.
What is the best way to schedule an appointment with Keith Stockerl-Goldstein?
Apply for one of the trials that Keith Stockerl-Goldstein is conducting.
What is the office address of Keith Stockerl-Goldstein?
The office of Keith Stockerl-Goldstein is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.